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Abstract 17 
In a randomized double-blind crossover trial, the effect of 8 weeks supplementation with grape 18 
and wine polyphenols on functional and structural vascular parameters and autonomic activity 19 
was evaluated in 40 essential hypertensive patients treated with diuretic monotherapy. 20 
Ambulatory blood pressure, brachial artery flow mediated dilation (FMD) and pulse-wave 21 
velocity (PWV) were measured at baseline and after each 8-week intervention. Forearm 22 
resistance artery endothelial function and muscle sympathetic nerve activity (MSNA) response to 23 
mental stress and cold-pressor test were measured in two separate sub-groups. No statistically 24 
significant differences were found across time or between groups in either blood pressure, FMD, 25 
PWV, resistance artery endothelial function. The MSNA response to the two stressors was non-26 
significantly attenuated after grape-wine polyphenol supplementation. These results do not 27 
support the hypothesis that daily consumption of a high dose of grape and wine polyphenols 28 
lowers blood pressure or affect vascular function in patients already on antihypertensive 29 
medication.  30 
KEYWORDS: Wine, grape, polyphenol, cardiovascular disease, endothelial function, blood 31 
pressure  32 
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1. Introduction  33 
Mediterranean dietary patterns may confer beneficial effects on the progression of cardiovascular 34 
disease (CVD)(Sofi, Abbate, Gensini, & Casini, 2010). These diets are particularly rich in 35 
polyphenols, which represent secondary plant metabolites purported to mediate these beneficial 36 
effects on human health (Rothwell et al., 2013; Vogiatzoglou et al., 2015). Wine is an important 37 
component of the Mediterranean diet and is rich in polyphenols. Epidemiological studies 38 
demonstrate that moderate wine drinkers show lower mortality rates than non-drinkers (O'Keefe, 39 
Bhatti, Bajwa, DiNicolantonio, & Lavie, 2014) and potential protective effects of grape derived 40 
polyphenols against certain types of cancer, diabetes, obesity and cardiovascular disease have 41 
also been reported (Shahidi & Ambigaipalan, 2015). Polyphenols are potent antioxidants and 42 
have been shown to have anti-inflammatory and anti-atherogenic properties, such as inhibition of 43 
peroxyl radical-induced DNA strand breakage, protection of low density lipoprotein from 44 
oxidative damage, inhibition of platelet aggregation and of the expression of adhesion molecules 45 
and of monocytes/macrophages adhesion to the endothelium (de Camargo, Regitano-d'Arce, 46 
Biasoto, & Shahidi, 2014; Denny et al., 2014; Dohadwala & Vita, 2009). Moreover, recent work 47 
has also suggested these compounds act as inhibitors of alpha-glucosidase and lipase activity (de 48 
Camargo, Regitano-d'Arce, Biasoto, & Shahidi, 2016). Consequently, these properties may 49 
contribute to the health benefits of increased polyphenol intake in humans. 50 
 51 
Hypertension is one of the primary risk factors for CVD-related morbidity and mortality. Human 52 
intervention studies demonstrate that consumption of products rich in grape and wine 53 
polyphenols lower blood pressure, although the data are not entirely consistent (Botden et al., 54 
2012; Chiva-Blanch et al., 2012; Dohadwala et al., 2010; Droste et al., 2013; Mellen, Daniel, 55 
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Brosnihan, Hansen, & Herrington, 2010; van Mierlo, Zock, van der Knaap, & Draijer, 2010; 56 
Ward et al., 2005). The blood pressure lowering effects of grape-derived polyphenols may be 57 
mediated by improvement in resistance artery function and/or decreases in peripheral artery 58 
vascular tone. For example, studies with wine and grape extracts have demonstrated improved 59 
endothelial function in conduit and resistance arteries (Botden et al., 2011; Siasos et al., 2014; 60 
Stein, Keevil, Wiebe, Aeschlimann, & Folts, 1999), possibly via nitric oxide dependent pathways 61 
(Botden et al., 2011). In addition, studies with tea and cocoa, i.e. prominent sources of dietary 62 
polyphenols, found improvement in indirect measures of sympathetic nervous system (SNS) 63 
activity patterns, possibly contributing to lowering of peripheral vascular tone (Steptoe et al., 64 
2007; Wirtz et al., 2014). 65 
 66 
To date, most previous studies investigating the blood pressure lowering effects of wine and/or 67 
grape extracts were conducted in healthy participants or in non-medicated hypertensives (Li, 68 
Zhao, Tian, Chen, & Cui, 2015). Such studies poorly translate to the majority of hypertensive 69 
patients who typically receive lifelong antihypertensive medication. Accordingly, the objective 70 
of the current study was to determine whether 8-week consumption of a polyphenol-rich grape-71 
wine extract mix affect ambulatory blood pressure, endothelial function and muscle sympathetic 72 
nerve activity (MSNA) in drug treated patients with essential hypertension. We hypothesized 73 
that intake of a high daily dose of polyphenols lowers blood pressure, regardless of 74 
antihypertensive medication use, an effect mediated through improvement in resistance artery 75 
endothelial function and reduction in MSNA. 76 
 77 
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2. Methods 78 
2.1.  Participants 79 
Fifty-one hypertensive patients on diuretic monotherapy were recruited from the outpatient clinic 80 
of the University of Pisa (starting December 2009). Inclusion criteria were office systolic BP 81 
values ≥140 mm Hg and/or office diastolic BP values ≥90 mm Hg, which were confirmed on 82 
repeated occasions within one month according to current guidelines, if untreated or controlled 83 
(BP<140-90 mmHg) by diuretic therapy (Mancia et al., 2013). Exclusion criteria were as 84 
follows: previous cardiovascular or cerebrovascular events, clinically significant arrhythmia, 85 
diabetes mellitus, smoking, clinically apparent liver disease or kidney damage, current treatment 86 
with statins and/or hormone replacement therapy, reported alcohol consumption > 28 units/week. 87 
The study protocol was approved by the local ethical committee of University Hospital of Pisa 88 
and was in accordance with guidelines in the Declaration of Helsinki. Patients gave their written 89 
informed consent to participation in the study after an explanation of its nature and purpose. 90 
 91 
2.2. Experimental Design 92 
This study adopted a randomized, placebo-controlled, double-blind crossover design with two 8-93 
week intervention periods. At an initial screening visit, eligible patients were given dietary 94 
advices for a standard Mediterranean diet and informed to drink no more than two units of 95 
alcohol per day. Moreover, the patients were instructed to moderate their intake of polyphenol-96 
rich products throughout the study (less than two daily cups of coffee and/or tea; avoid dark 97 
chocolate and red wine). For the 48-h preceding the experimental days, subjects were instructed 98 
to avoid consumption of all polyphenol-rich foods in order to fully exclude the impact of 99 
background dietary polyphenols. 100 
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 101 
Following a 4-week run-in period, patients were randomly allocated to either grape-wine extract 102 
or placebo treatments. After an 8-week intervention, patients were crossed over to the other 103 
treatment. The diuretic dose was kept stable throughout the run-in and intervention periods. 104 
Measurements were performed on three different occasions, at baseline and immediately after 105 
each 8-week treatment period. Invasive measurements (forearm resistance vessel endothelial 106 
function and muscle sympathetic nerve activity) were conducted before and after the first 8-week 107 
intervention period only. Therefore, data on these measures are available in two different subsets 108 
of the study population (Fig. 1). 109 
 110 
2.3. Intervention 111 
The grape-wine extract mix comprised of 870 mg of red wine extract (Provinols™; Seppic, 112 
France) and 540 mg grape juice extract (MegaNatural™ Rubired; Polyphenolics, USA). The 113 
total polyphenol content of the extract mix amounted to 800 mg (defined as gallic acid 114 
equivalents): 550 mg from the wine extract and 250 mg from the grape juice extract.  115 
 116 
The polyphenol composition of the red wine- and grape juice extracts was determined in 117 
duplicate by means of high-performance liquid chromatography with diode array detection 118 
(HPLC-DAD) and HPLC with electrospray ionization mass spectrometry (HPLC-ESI-MS) using 119 
an Agilent HPLC series 1100 equipped with ChemStation software as previously reported (van 120 
Dorsten et al., 2010). For determination of anthocyanins a mobile phase consisting of water, 121 
formic acid and acetonitrile and a Betasil C18 column (Thermo Scientific, 150 x 2.1 mm i.d., 5 122 
µm particle size), with a Guard Column Cartridge was used. The individual anthocyanins were 123 
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quantified via DAD using a calibration curve of cyanidin 3-O-glucoside (Roth, Karlsruhe, 124 
Germany), including a molecular weight correction factor (Chandra, Rana, & Li, 2001). The 125 
identification and peak assignment were accomplished by simultaneous HPLC-ESI-MS analysis 126 
in the positive ion mode (selected ion monitoring) as well as in scan mode. Increase of the 127 
fragmentor voltage resulted in cleavage of the pigments and release of the anthocyanidin 128 
aglycones, which were identified by comparison of their m/z ratios with those described in the 129 
literature (Wang, Race, & Shrikhande, 2003).  130 
For determination of catechins, flavonols and stilbenes a mobile phase consisting of water, acetic 131 
acid and acetonitrile and a Synergi Hydro-RP column, (Phenomenex, 250 x 2mm i.d.; 5µm 132 
particle size) with a Guard Column Cartridge, was used. The individual phenolic acids, 133 
catechins, flavonols and stilbenes were quantified using a calibration curve of the corresponding 134 
standard compounds (gallic acid, protocatechuic acid, p-hydroxybenzoic acid, vanillic acid, 135 
caffeic acid, syringic acid, p-coumaric acid, ferulic acid, chlorogenic acid, gallocatechin, 136 
catechin, epicatechin, epicatechin-3-gallate, resveratrol (Sigma, St. Louis, USA); ellagic acid 137 
(Roth, Karlsruhe, Germany); myricetin, kaempferol-3-O-rutinoside (Extrasynthése, Lyon, 138 
France); quercetin-3-D-galactoside, quercetin-3--D-glucoside, quercetin-3-rhamnoside, 139 
quercetin (Fluka, Buchs, Switzerland)). The identification and quantification was accomplished 140 
by HPLC-ESI-MS analysis in the negative ion mode (selected ion monitoring). 141 
 142 
Analysis of the extracts revealed that each daily dose of the wine and grape extract mix 143 
contained approximately 140 mg anthocyanidins and 40 mg flavanols along with small amounts 144 
of flavonols, phenolic acids and stilbenes with the remaining polyphenolic portion of the extracts 145 
consisting of unidentified polymeric proanthocyanidins. Detailed compositional information of 146 
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the extracts are reported in Table 1. Each daily dose was provided in six gelatine capsules 147 
(Capsugel Conisnap no. 0) which were taken at breakfast. Identical capsules containing 148 
microcrystalline cellulose (Avicel PH101, FMC Biopolymer) served as the placebo. Subjects 149 
were instructed to return all unused capsules at the end of each intervention period and 150 
compliance was determined by capsule counting. Average compliance was 88%. 151 
 152 
2.4. Experimental Measures 153 
2.4.1. Ambulatory blood pressure 154 
At baseline and at the end of each 8-week intervention period, a 24-hour ambulatory blood 155 
pressure recording was performed using a Spacelabs monitor (Type 90 217; Spacelabs Medical 156 
Inc.) placed on the non-dominant arm. Blood pressure was recorded at 15-min intervals 157 
throughout the day and at 20-min intervals during the night (11 PM – 8 AM).  158 
 159 
2.4.2. Forearm resistance vessel endothelial function 160 
In a subset of 25 subjects (n=13 grape-wine, n=12 control), forearm resistance artery endothelial 161 
function was evaluated before and after the first 8-week intervention period by means of the 162 
isolated and perfused forearm technique as described previously (Virdis et al., 2001). Briefly, the 163 
brachial artery of the non-dominant arm was cannulated for vasoactive drug infusion at 164 
systemically ineffective doses. Forearm blood flow was measured in the experimental and 165 
contralateral forearm by strain-gauge venous occlusion plethysmography. Forearm blood flow 166 
was calculated using standard formulae and expressed as ml/100 ml forearm volume/min. To 167 
account for effects of potential arterial pressure variations, forearm vascular resistance (FVR) 168 
was calculated by dividing mean arterial pressure by forearm blood flow.  169 
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 170 
Endothelium-dependent vasodilation was assessed by a dose-response curve to intra-arterial 171 
acetylcholine (ACh; cumulative increase in infusion rates by 0.15, 0.45, 1.5, 4.5 and 15 mg/100 172 
ml forearm tissue per min, 5 min each dose). To evaluate the NO availability, the response to 173 
ACh was repeated in the presence of the NOS inhibitor NG-monomethyl-L-arginine (L-NMMA, 174 
4 mmol/min) (Virdis et al., 2001). Because L-NMMA modifies blood flow, sodium nitroprusside 175 
(SNP; 0.2 mg/100 mL tissue/min for 5 min) was co-infused to neutralize the L-NMMA-induced 176 
vasoconstriction and restore baseline FVR. The role of reactive oxygen species (ROS) generation 177 
on endothelial function was investigated by repeating the ACh-infusion protocol under co-178 
infusion of ascorbic acid (8 mg/100 mL forearm tissue/min) as well as during co-infusion of L-179 
NMMA and ascorbic acid. L-NMMA and ascorbic acid infusion were started 10 min before 180 
ACh-infusion and continued throughout this protocol. A 30 min washout was allowed between 181 
each dose–response curve, whilst this washout was consistently prolonged to 60 min when L-182 
NMMA was infused. Finally, endothelium-independent vasodilation was assessed with a dose-183 
response curve to intra-arterial infusion of SNP (1, 2, and 4 mg/100 mL forearm tissue/min, 5 184 
min each dose). To avoid making multiple comparisons, the responses to the vasoactive 185 
substances were expressed as the area under the curve (AUC) of change in FVR from baseline, 186 
expressed in arbitrary units. Analysis was performed by a single investigator (A.V.) blinded to 187 
the patient’s allocation to treatment. 188 
 189 
2.4.3. Muscle sympathetic nerve activity 190 
In a subset of 16 subjects (n=8 grape-wine, n=8 control), multiunit recording of efferent 191 
postganglionic muscle sympathetic nerve activity (MSNA) of the peroneal nerve was obtained 192 
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using microneurography before and after the first 8-week intervention period. Briefly, a tungsten 193 
microelectrode with an uninsulated 1–5-μm-diameter tip (Medical Instruments, University of 194 
Iowa) was transcutaneously inserted in the peroneal nerve just posterior to the fibular head, as 195 
previously described (Bruno, Sudano, Ghiadoni, Masi, & Taddei, 2011). A reference electrode 196 
was inserted subcutaneously 1 to 3 cm from the recording site. The signal was integrated with a 197 
0.1-s time constant, amplified with a gain of 50,000–80,000, band-pass filtered (700–2000 Hz), 198 
and acquired at 1000 Hz through a digital acquisition system (ACQ-16; Gould Electronics). 199 
MSNA was identified according to previously outlined criteria (Bruno et al., 2011; Delius, 200 
Hagbarth, Wallin, & Hongell, 1972). Obtained neurograms were recorded together with BP and 201 
heart rate by means of dedicated computer software (Ponemah; LDS). Recordings were 202 
considered acceptable if the signal:noise ratio exceeded the value of 3. MSNA responses were 203 
measured at rest and during 2-min of mental stress (serial 7 subtraction (Birkett, 2011)) followed 204 
by 2-min of cold pressor test. Data were quantified as bursts/min (burst frequency) and 205 
bursts/100 heart beats (burst incidence). MSNA was analysed by visual inspection by a single 206 
investigator (R.M.B.) blinded to the patient’s allocation to treatment.  207 
 208 
2.4.4. Brachial artery flow mediated dilation 209 
Before and after both 8-week interventions, we examined brachial artery flow meditated dilation 210 
(FMD) using high-resolution ultrasound with a 10 MHz linear array transducer (MyLab25, 211 
ESAOTE, Florence, Italy), following recent guidelines as previously described (Thijssen et al., 212 
2011). Endothelium-independent dilation was obtained by sublingual administration of 25 μg 213 
glyceryl trinitrate (GTN). FMD and the response to GTN were calculated as the maximal 214 
percentage increase in diameter. Analysis of changes in brachial artery diameter was performed 215 
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using a real-time computerized edge detection system, which is independent of investigator bias 216 
(Gemignani, Faita, Ghiadoni, Poggianti, & Demi, 2007; L. Ghiadoni et al., 2012) by a single 217 
investigator (L.G.) blinded to patient’s allocation to treatment. 218 
 219 
2.4.5. Arterial stiffness and wave reflection 220 
Before and after both 8-week interventions, we assessed arterial tonometry according to 221 
international recommendations using procedures previously described (Plantinga et al., 2007). A 222 
hand held probe was placed on the radial artery and 10–15 subsequent images were recorded. 223 
Radial pressure waveform was transformed into aortic pressure waveform by pulse wave 224 
analysis (PWA) (SphygmoCor, AtCor Medical) using a validated transfer function. Two 225 
successive measurements were recorded and averaged. Augmented pressure was calculated as 226 
the difference between the second systolic peak and the first systolic peak, and augmentation 227 
index (AIx) was calculated as the ratio between augmented pressure and pulse pressure. Since 228 
AIx is correlated with heart rate, values have been normalized at a heart rate of 75 beats per 229 
minute. Aortic pulse wave velocity (PWV) was assessed with the same device, sequentially 230 
recording pressure waveforms at the femoral and carotid site. PWV was calculated as the ratio of 231 
the surface distance between the two recording sites (subtracting the carotid–sternal notch 232 
distance from the femoral–sternal notch distance) and wave transit time. Analysis was performed 233 
by a single investigator (R.M.B.) blinded to patient’s allocation to treatment 234 
 235 
2.5. Statistical analysis 236 
All statistical analyses were conducted using JMP version 11.0 (SAS Institute Inc., Cary, NC, 237 
USA). Descriptive statistics are presented as means and standard deviation (SD). All data are 238 
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reported as LSmeans (95%CI), unless reported otherwise and was considered statistically 239 
significant at P<0.05. The change in outcome parameters of the invasive measurements (parallel-240 
group study; FVR, MSNA) were analysed using a repeated measures ANCOVA with treatment 241 
as between-subject effect and period, ACh dose (for the FVR group) and stimulus (for the 242 
MSNA group) as within-subject effects and resting baseline measurement as covariate. The 243 
change in outcome parameters of the non-invasive measurements (FMD, PWV, PWA, blood 244 
pressure), which were performed before and after both interventions, were analysed using a 245 
mixed model with subject as random factor, treatment and period as fixed effects and the 246 
baseline measurement as covariate. 247 
 248 
Power calculations indicated that: 40 subjects (20 per intervention arm) would be sufficient to 249 
detect an absolute difference of 1% in the FMD response between treatments in a crossover 250 
study design with a 80% power and a 5% significance; 20 subjects (10 per intervention arm) 251 
would be sufficient to detect a difference between treatments in the expected mean change of 252 
20% in the percent L-NMMA inhibition on ACh-induced vasodilation in the forearm 253 
microcirculation (80% power, 5% significance in parallel group study design); 16 subjects (8 per 254 
intervention arm) are sufficient to detect a difference between treatments in the expected mean 255 
change of 10% in MSNA (burst/minute) (80% power, 5% significance in a parallel study 256 
design). In the laboratory performing the evaluation, the coefficients of variation of the latter 257 
variables is less than 5% (Bruno et al., 2011; Pedrinelli, Taddei, Graziadei, & Salvetti, 1986).  258 
 259 
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3. Results 260 
Of the 51 subjects screened for inclusion, three were classified as screening failures as they all 261 
demonstrated blood pressure not ≤140/90 mmHg at the end of the run-in period. A further eight 262 
subjects did not complete the study procedures for personal reasons – five decided to not 263 
continue after Visit 0 and three more after Visit 1 (Fig. 1). No subjects were excluded during 264 
blind review. The Per Protocol and Intention to Treat study populations are thus equal and 265 
consist of 41 subjects that completed all study procedures of the first phase of the study and 40 266 
subjects that completed all study procedures of the second phase of the study. Baseline 267 
characteristics are described in Table 2. 268 
 269 
3.1. 24-hour ambulatory blood pressure, large artery endothelial function and stiffness 270 
No statistically significant differences were found across time or between groups in either 271 
systolic- or diastolic blood pressure, FMD, GTN mediated dilation and PWV. Regarding PWA, 272 
no statistically significant changes were found across time or between groups in either central 273 
pulse pressure, augmentation pressure, AIx or AIx75 (Table 3). 274 
 275 
3.2. Endothelium-dependent dilation in the microcirculation 276 
In both the grape-wine and placebo groups, the decrease in FVR in response to ACh infusion 277 
was larger after the 8-week intervention period (Time effect, P < 0.001, Fig. 2). No Treatment 278 
effect or Time*Treatment*ACh Dose interaction was found, indicating that the change in FVR 279 
response to ACh-infusion was comparable between groups. Analysing the area-under-the-curve 280 
of the FVR response to ACh also revealed a change after the intervention period (Time effect P < 281 
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0.001) that was not different between the two groups (Treatment effect, P = 0.19, 282 
Time*Treatment interaction, P = 0.43, Fig. 3). 283 
 284 
3.3. Endothelium-independent dilation in the microcirculation 285 
FVR responses to SNP infusion were greater after the 8-week intervention period (Time effect, P 286 
= 0.02, Fig. 3). No Treatment effect or Time*Treatment interaction was apparent however (P = 287 
0.16 and P = 0.28 respectively). 288 
 289 
3.4. Nitric Oxide availability & ROS production 290 
Decreases in FVR in response to ACh were inhibited through co-infusion of L-NMMA, whilst 291 
the magnitude of inhibition was increased after the 8-week intervention period (Time effect, P = 292 
0.02, Fig. 3). This indicates a larger contribution of NO to resistance artery endothelial function 293 
after the intervention period. However, the magnitude of change across time did not differ 294 
between groups (Fig. 3). 295 
 296 
Co-infusion of Vitamin C with ACh caused a larger decrease in FVR at baseline, indicating a 297 
role for ROS production to increase resting vascular tone. The intervention was associated with 298 
an attenuated decrease in FVR during co-infusion of Vitamin C and ACh (“Time effect”, P = 299 
0.01), whilst this effect was similarly present in both groups (Fig. 3). Finally, we found that co-300 
infusion of Vitamin C potentiated the increase in FVR induced by L-NMMA. After the 301 
intervention, the potentiating effect of Vitamin C on L-NMMA was reduced (Time effect, P = 302 
0.03), indicating that the improvement in L-NMMA responses after the intervention are, in part, 303 
mediated through decreased ROS production. Nonetheless, no Treatment effects or 304 
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Time*Treatment interactions were found for the co-infusion of Vitamin C and L-NMMA (Fig. 305 
3). 306 
 307 
3.5. Muscle sympathetic nervous activity 308 
Resting MSNA burst frequency and burst incidence did not change in either grape-wine or 309 
placebo groups after the 8-week intervention period (Fig. 4). The increase in MSNA burst 310 
frequency in response to mental stress and cold pressor test was comparable after the 8-week 311 
interventions. However, MSNA burst incidence during mental stress and the cold pressor test 312 
was attenuated after the 8-week intervention in the grape-wine group, whilst MSNA burst 313 
incidence during these tests increased after placebo. These differences were not statistically 314 
significant though (Fig. 4, Time*Treatment interaction, P = 0.06, Time*Treatment*Stimulus 315 
interaction, P= 0.24). The increase in mean arterial pressure in response to mental stress and cold 316 
pressor test was comparable after the 8-week interventions. However, a statistically significant 317 
Time*Treatment interaction was found for the increase in heart rate in response to mental stress 318 
and cold pressor test. More specifically, heart rate during mental stress and the cold pressor test 319 
increased after the 8-week intervention in the grape-wine group, whilst the increase was 320 
attenuated during these tests increased after placebo (Table 4). 321 
 322 
4. Discussion 323 
The aim of this study was to determine whether a high daily intake of grape and wine 324 
polyphenols affected blood pressure, endothelial function and MSNA in treated hypertensive 325 
subjects. We observed that 8 weeks supplementation with a mixture of grape and wine extracts, 326 
providing a daily dose of 800 mg polyphenols, did not result in changes in 24-hour ambulatory 327 
blood pressure compared to placebo. Furthermore, we found no effects of dietary intake of 328 
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polyphenols on resistance- or conduit artery endothelial function, arterial stiffness or measures of 329 
resting SNS activity. However, we found an attenuated increase in MSNA during sympathetic 330 
stimulation in those who received daily grape-wine polyphenol supplementation. Taken together, 331 
these data suggest that neither ambulatory 24-h blood pressure nor measures of vascular function 332 
or tone are affected by grape and wine polyphenol intake in patients receiving antihypertensive 333 
medication. Possible beneficial effects of polyphenols may however be present by attenuating 334 
increases in autonomic stress reactivity, which is a possible determinant of poor cardiovascular 335 
outcome (Chida & Steptoe, 2010). 336 
 337 
A recent, well-controlled study in untreated mildly hypertensive subjects, found small reductions 338 
in blood pressure and endothelin-1 after 4 weeks’ twice daily consumption of grape and wine 339 
polyphenols (Draijer, de Graaf, Slettenaar, de Groot, & Wright, 2015). Moreover, a recent meta-340 
analysis of 10 studies (including mostly un-medicated subjects) indicated a small (1.5 mmHg) 341 
reduction in systolic blood pressure at an average dose of grape derived polyphenols close to that 342 
of our study (Li et al., 2015). In the current “diseased” study population, it is plausible that a 343 
longer treatment duration may be needed to elicit a blood pressure lowering effect. Our 344 
observations are however in agreement with several previous studies, all which have found no 345 
effects of grape and/or wine polyphenols on blood pressure or measures of vascular function and 346 
stiffness in both healthy subjects and those with elevated CVD risk (Botden et al., 2012; Droste 347 
et al., 2013; Mori et al., 2016; Ras et al., 2013; van Mierlo et al., 2010; Ward et al., 2005) .  348 
 349 
Effects on blood pressure and vascular structure and function have been ascribed various 350 
different individual polyphenols and polyphenol classes present in grape-derived foods, with 351 
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flavanols (e.g. catechin, epicatechin, epigallocatechin gallate) having the most robust evidence at 352 
this time (Kay, Hooper, Kroon, Rimm, & Cassidy, 2012). Isolated anthocyanins, stilbenes and 353 
flavonols have to varying extents also been associated with either beneficial effects on blood 354 
pressure, endothelial function or both, although the evidence is not entirely consistent 355 
(Rodriguez-Mateos et al., 2013; Wong et al., 2013; Zhu et al., 2016; Zhu et al., 2011). As such 356 
we opted to utilise a mixture of two grape products in order to cover the spectrum of grape-357 
related polyphenols normally found in the diet. 358 
 359 
Polyphenols are thought to improve endothelial function by increasing bioavailability of NO. 360 
Specifically, polyphenols may stimulate activity of endothelial nitric oxide synthase (eNOS) and 361 
prevent superoxide-mediated NO breakdown (Fitzpatrick, Hirschfield, Ricci, Jantzen, & Coffey, 362 
1995; Grassi et al., 2008). We specifically chose to include only subjects on diuretic 363 
monotherapy to avoid direct vascular effects of most other commonly prescribed anti-364 
hypertensive agents (Ghiadoni, Taddei, & Virdis, 2012). Thiazide diuretics, which were 365 
prescribed to the patients in our study, are known to have no effects on endothelial function 366 
(Chung, Beevers, & Lip, 2004; Klingbeil et al., 2003; Yamanari, Nakamura, Miura, Yamanari, & 367 
Ohe, 2009). Therefore it seems unlikely that the use of diuretics would have obscured any 368 
potential effects of grape and wine polyphenols on measures of endothelial function in our study. 369 
 370 
Polyphenols are rapidly metabolized and eliminated from the circulation with peak plasma 371 
concentrations usually occurring a few hours after intake (Manach, Williamson, Morand, 372 
Scalbert, & Remesy, 2005). Accordingly, several studies have found that intake of grape derived 373 
polyphenols resulted in increases in brachial artery FMD 30 to 120 minutes after intake (Li, 374 
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Tian, Zhao, Chen, & Cui, 2013). FMD and resistance artery endothelial function in our study 375 
was measured several hours after intake of the last dose of polyphenols. It is plausible that a 376 
transient improvement in endothelial function might have been missed due to the single daily 377 
dose regime and timing of the measurements. To our knowledge only one other study 378 
investigated the effects of red wine polyphenols on resistance artery responses to infusion of 379 
endothelium-dependent and independent agonists (Botden et al., 2011). In contrast to our 380 
findings, increases in both ACh and SNP mediated vasodilation were seen after daily 381 
consumption of red wine for 3 weeks in healthy young women. Time of wine ingestion (acute 382 
and the evening prior to measurements) differed from our study. This study did not include a 383 
control group however, so it is unclear what portion of the observed effects could be explained 384 
by the alcohol content of the wine.  385 
 386 
The polyphenol content of the background diet may also explain the lack of effects on blood 387 
pressure or endothelial function in the current study. Several prospective follow-up studies have 388 
found non-linear dose-response relationships between flavonoid intake and CVD risk, with low 389 
risks already occurring at relatively low levels of intake (Cassidy et al., 2011; McCullough et al., 390 
2012; Mink et al., 2007). Moreover, dose-response studies of tea and cocoa flavonoids have 391 
found that the relative increases in FMD become smaller with increasing doses of flavonoids 392 
(Grassi et al., 2015; Grassi et al., 2009). Given that the average polyphenol content of the Italian 393 
diet is relatively high (Vogiatzoglou et al., 2015), it is plausible that additional grape and wine 394 
polyphenols would not have caused any demonstrable hemodynamic or vascular effects.  395 
 396 
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It is well established that the SNS is involved in regulation of blood pressure and vasomotor tone 397 
(Bruno et al., 2012). Studies of tea and cocoa polyphenols have found effects on indirect 398 
measures of SNS activity (Steptoe et al., 2007; Wirtz et al., 2014). This led to us hypothesize that 399 
grape and wine polyphenol consumption would affect resting SNS activity as well as the extent 400 
of SNS activation in response to various stimuli. We found no change in resting SNS activity in 401 
response to grape and wine polyphenol consumption. However, the extent of SNS activation by 402 
mental stress and the cold pressor test was attenuated in the subjects receiving grape and wine 403 
polyphenols. This finding may be of clinical significance as elevated sympathetic and 404 
cardiovascular reactivity to stressful stimuli has been associated with the development of 405 
hypertension and cardiovascular disease (Matsukawa et al., 1991; Park, Middlekauff, & 406 
Campese, 2012; Steptoe & Marmot, 2005).  407 
 408 
The renin–angiotensin system may interfere with the sympathetic function and inhibition of 409 
angiotensin converting enzyme activity (ACE) has been shown to affect MSNA (Grassi, 2016). 410 
Isolated polyphenols and polyphenol-rich foods have shown ACE inhibitory activity both in vitro 411 
and in vivo (Guerrero et al., 2012; Parichatikanond, Pinthong, & Mangmool, 2012; Persson, 412 
Persson, Hagg, & Andersson, 2010). Structure-activity relationship studies have found that the 413 
presence of: 1) a catechol group in the B-ring, 2) a double bond between C2 and C3 at the C-414 
ring, and 3) a ketone group in C4 at the C-ring are important determinants of the level of ACE 415 
inhibitory activity (Guerrero et al., 2012). A number of the polyphenols found in wine and grape 416 
extracts are known to directly interact with the sympathetic and central nervous systems which 417 
might explain the MSNA effects observed in the present study (Lee, Seo, & Lim, 2009; 418 
Shinohara et al., 2007; Wasowski & Marder, 2012). Notably resveratrol has been demonstrated 419 
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to inhibit agonist-induced catecholamine synthesis and secretion by inhibiting nicotinic 420 
acetylcholine receptor-ion channels in the adrenal medulla and sympathetic neurons in in vitro 421 
studies (Shinohara et al., 2007). It is also noteworthy that AIx was differentially modified 422 
(although in a non-significant manner) in the two intervention arms in the presence of similar 423 
values of AP and HR. This difference might be explained by the sympathoinhibitory effect of 424 
polyphenols suggested by the attenuation of autonomic reactivity to stress. Longer treatment 425 
might induce a greater reduction of AIx, contributing to a possible BP-lowering effect. These 426 
observations should be interpreted with caution though as the sub-group in which MSNA was 427 
measured was small (n=16) and the differences did not reach statistical significance.  428 
 429 
Limitations: We did not measure circulating or urinary levels of polyphenol metabolites. 430 
Therefore, we cannot comment on the bioavailability of the polyphenols from the encapsulated 431 
extracts provided in our study. However, after a previous 4-week intervention with the same type 432 
and dose of grape and wine extracts provided in capsules, we found significant elevations in the 433 
subject’s urinary excretion of a wide range of phenolic acids (van Dorsten et al., 2010). This 434 
suggest that at least a portion of the polyphenols from the grape and wine extracts or their 435 
metabolites formed in the body’s tissues or the colonic microflora will typically reach the 436 
circulation. The subgroups in which we measured FVR and SNS activity were quite small. 437 
However, both techniques are highly reproducible and sensitive enough to reveal subtle changes 438 
(Bruno et al., 2011; Pedrinelli et al., 1986). Strengths of this study include the double-blind 439 
crossover design, long duration and the use of accurate 24-hour ambulatory blood pressure 440 
measurements combined with gold-standard measures of resistance artery endothelial function 441 
and SNS activity in the same subjects. We observed a consistent absence of effects of grape and 442 
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wine polyphenols on resting blood pressure and across a range of integrated vascular and 443 
endothelial parameters related to its regulation. These observations support the robustness of our 444 
findings. 445 
 446 
In summary, this study does not support the hypothesis that 8 week once-daily consumption of a 447 
high dose of grape and wine polyphenols lowers resting blood pressure in subjects receiving 448 
antihypertensive medication. The potential of grape and wine polyphenols to attenuate over-449 
responsiveness of the SNS should be confirmed in larger, well-controlled studies set up for this 450 
purpose. Future studies should also determine which subclasses of polyphenols common to 451 
different foods can lower blood pressure and improve endothelial function. It should also be 452 
determined whether potential vascular and hemodynamic effects vary by subject’s health- and 453 
treatment status. 454 
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Figure captions 693 
Fig. 1. Enrolment, randomization and experimental design of the study 694 
 695 
Fig. 2. Change in forearm vascular resistance induced by increasing doses of acetylcholine at 696 
before (Visit 0, closed symbols) and after 8 weeks’ intervention (Visit 1, open 697 
symbols) with grape-wine extract (A) or placebo groups (B). P-values refer to a 3-way 698 
repeated measures ANCOVA with treatment (grape-wine vs placebo) as between-699 
subject effect, period (Visit 0 vs 1) and stimulus as within-subject effects and resting 700 
baseline measurement as covariate. Data are presented as LSmeans (95% CI). 701 
 702 
Fig. 3. Change in forearm vascular resistance expressed as area under curve at baseline (grey 703 
bars) and after 8 weeks (black bars) in the grape-wine and placebo groups. Data are 704 
presented as LSmeans (95% CI). 705 
 706 
Fig. 4. Change in MSNA burst frequency (A) and burst incidence (B) response to mental stress 707 
and cold pressor test before (Visit 0, closed symbols) and after 8 weeks intervention 708 
(Visit 1, open symbols) with grape-wine extract or placebo. P-values refer to a 3-way 709 
repeated measures ANCOVA with treatment (grape-wine vs placebo) as between-710 
subject effect, period (Visit 0 vs 1) and stimulus as within-subject effects and resting 711 
baseline measurement as covariate. Data are presented as LSmeans (95% CI). 712 
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Table 1. Polyphenol content of the red wine and grape juice extracts 714 
 
Wine 
(mg/g) 
Grape juice 
(mg/g) 
Total in 870 mg wine + 
540 mg grape juice 
Anthocyanins  21.50 225.85 140.66 
delphinidin 3,5-diglucoside 0.00 3.59 1.94 
cyanidin 3,5-diglucoside 0.00 1.78 0.96 
delphinidin 3-glucoside 0.47 3.23 2.15 
petunidin 3,5-diglucoside 0.00 10.32 5.57 
cyanidin 3-glucoside 0.11 1.29 0.79 
peonidin 3,5-diglucoside 0.00 46.05 24.87 
malvidin 3,5-diglucoside  0.00 82.75 44.69 
peonidin 3-glucoside 1.76 5.40 4.45 
malvidin 3-glucoside 9.26 11.66 14.35 
delphinidin 3-coumaroyl-5-diglucoside 0.00 3.53 1.91 
cyanidin 3-coumaroyl-5-diglucoside 0.00 0.93 0.50 
petunidin 3-coumaroyl-5-diglucoside 0.00 7.33 3.96 
delphinidin 3-coumaroylglucoside 0.35 1.09 0.90 
peonidin 3-coumaroyl-5-diglucoside 0.00 5.37 2.90 
malvidin 3-coumaroyl-5-diglucoside 0.00 34.51 18.63 
petunidin 3-coumaroylglucoside 0.46 0.70 0.78 
peonidin 3-coumaroylglucoside 0.80 0.65 1.04 
malvidin 3-coumaroylglucoside 5.36 5.66 7.72 
petunidin 3-glucoside 1.29 0.00 1.12 
peonidin 3-acetylglucoside 0.15 0.00 0.13 
malvidin 3-acetylglucoside 1.49 0.00 1.30 
Phenolic acids  7.89 5.22 9.68 
caffeic acid 1.27 0.30 1.26 
p-coumaric acid 0.68 0.46 0.84 
ferulic acid 0.07 0.09 0.11 
gallic acid 1.46 2.02 2.36 
protocatechuic acid 0.62 0.30 0.70 
p-hydroxybenzoic acid  0.20 0.08 0.21 
vanillic acid 0.39 0.19 0.45 
syringic acid 1.02 1.00 1.42 
caftaric acid 0.60 0.18 0.62 
coutaric acid 0.79 0.09 0.73 
fertaric acid 0.52 0.30 0.61 
ellagic acid 0.24 0.19 0.31 
chlorogenic acid (5-O-caffeoylquinic 
acid) 
0.03 0.03 0.05 
Flavanols 45.18 0.40 39.52 
catechin 12.85 0.13 11.25 
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epicatechin 12.17 0.10 10.64 
procyanidin B1 9.97 0.05 8.70 
procyanidin B2 6.78 0.02 5.90 
procyanidin C1 1.19 0.00 1.04 
gallocatechin 0.62 0.05 0.56 
epigallocatechin 0.20 0.00 0.17 
epicatechin-3-O-gallate 1.41 0.06 1.25 
Flavonols  4.82 9.48 9.31 
hyperoside (quercetin-3-O-galactoside) 0.13 0.10 0.17 
miquelianin (quercetin-3-O-
glucuronide) 
1.78 2.49 2.89 
isoquercitrin (quercetin-3-O-glucoside) 0.66 1.39 1.32 
qercitrin (quercetin-3-O-rhamnoside) + 
astragalin (kaempferol-3-O-glucoside) 
0.12 0.11 0.16 
quercetin 0.47 1.17 1.04 
kaempferol 0.05 0.16 0.13 
myricetin-3-O-glucoside 0.94 2.45 2.14 
myricetin 0.67 1.61 1.46 
Stilbenes  0.97 0.15 0.92 
polydatin 1* 0.37 0.06 0.35 
polydatin 2* 0.36 0.07 0.35 
trans-resveratrol  0.24 0.02 0.22 
 715 
  716 
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Table 2. Subject characteristics from hypertensive patients included in the trial. Data are 717 
presented as mean ± SD. 718 
Characteristics   
N 40  
Gender, females/males 4/36  
Age (years) 46.8 ± 9.0 
Weight (kg) 80.4 ± 8.2 
Body Mass Index (kg/m2) 26.1 ± 2.1 
Systolic blood pressure (mmHg) 141.1 ± 8.0 
Diastolic blood pressure (mmHg) 87.9 ± 5.0 
Plasma glucose (mg/dL) 93.0 ± 10.7 
Total cholesterol (mg/dL) 194.0 ± 38.0 
HDL cholesterol (mg/dL) 52.0 ± 12.0 
LDL cholesterol (mg/dL) 119.6 ± 33.5 
Triacylglycerol (mg/dL) 104.0 ± 51.6 
  719 
Greyling et al.                       Blood pressure effect of grape polyphenols in treated hypertensives  37 
Table 3. Hemodynamic and vascular measurements at baseline and the end of the grape-wine 720 
and placebo intervention periods. Data are presented as raw unadjusted means ± SD. 721 
 Baseline Grape-Wine Placebo P-value* 
24-h SBP (mmHg) 134 ± 9 131 ± 9 131 ± 9 0.9 
24-h DBP (mmHg) 81 ± 8 79 ± 8 79 ± 8 0.7 
24-h HR (bpm) 68 ± 9 68 ± 9 67 ± 8 0.5 
Day-time SBP (mmHg) 138 ± 10 136 ± 10 135 ± 9 0.8 
Day-time DBP (mmHg) 85 ± 8 83 ± 8 83 ± 8 0.8 
Day-time HR (bpm) 71 ± 9 72 ± 10 71 ± 9 0.3 
Night-time SBP (mmHg) 127 ± 9 125 ± 10 125 ± 9 0.6 
Night-time DBP (mmHg) 75 ± 8 73 ± 8 74 ± 8 0.4 
Night-time HR (bpm) 63 ± 9 62 ± 8 62 ± 8 0.7 
Baseline BAD (mm) 4.4 ± 0.8 4.5 ± 0.8 4.4 ± 0.8 0.07 
FMD (%) 4.8 ± 2.6 5.0 ± 2.7 5.2 ± 3.1 0.6 
GTN (%) 7.8 ± 3.8 7.2 ± 4.6 7.2 ± 3.1 0.9 
PWV (m/s) 7.9 ± 1.1 7.8 ± 1.1 7.7 ± 1.2 0.6 
Central PP (mmHg) 45.8 ± 10.2 44.2 ± 8.8 44.2 ± 8.7 0.9 
AIx (%) 27.9 ± 20 23.1 ± 12.5 24 ± 11.3 0.5 
AIx75 (%) 21.4 ± 13.6 18.3 ± 11.7 21.0 ± 14.8 0.2 
AP (mmHg) 13 ± 7.6 11.8 ± 8.4 12.2 ± 7.6 0.7 
SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; BAD, Brachial Artery Diameter; 722 
FMD, Flow Mediated Dilation; GTN, Glycerol Trinitrate induced dilation; PWV, Pulse Wave 723 
Velocity; PP, pulse pressure; AIx, Augmentation Index; AIx75, Augmentation Index corrected for 724 
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heart rate of 75 bpm; AP, Augmentation Pressure; * P-value refers to a mixed model with subject 725 
as random factor, treatment and period as fixed effects and the baseline measurement as 726 
covariate.   727 
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Table 4. Heart rate and blood pressure responses to mental stress and cold pressor test at 728 
baseline and the end of the grape-wine and placebo intervention periods. Data are presented as 729 
raw unadjusted means ± SD. 730 
 Grape-Wine Placebo ANCOVA P-value* 
Heart rate 
(beats/min) 
Visit 0 Visit 1 Visit 0 Visit 1 Time*Treatment 
Time*Treatment
*Stimulus 
Resting 62 ± 7 61 ± 10 69 ± 13 66 ± 12 
0.03 0.66 MS’2 71 ± 11 74 ± 12 81 ± 13 78 ± 10 
CPT’2 67 ± 17 71 ± 13 76 ± 15 74 ± 13 
MAP (mmHg) Visit 0 Visit 1 Visit 0 Visit 1 Time*Treatment 
Time*Treatment
*Stimulus 
Resting 100 ± 9 100 ± 12 104 ± 11 103 ± 12 
0.72 0.99 MS’2 114 ± 13 114 ± 14 115 ± 14 114 ± 13 
CPT’2 118 ± 15 122 ± 27 119 ± 16 121 ± 14 
MAP, Mean Arterial Pressure; MS’2, 2 min mental stress; CPT’2, 2 min cold pressor test. *P-731 
value refers to a repeated measures ANCOVA with treatment as between-subject effect, period, 732 
and stimulus as within-subject effects and resting baseline measurement as covariate. 733 
  734 
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Fig. 1. 735 
 736 
  737 
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Fig. 2. 738 
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Fig. 3. 741 
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Fig. 4. 744 
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